Get started

Ocugen

Trading Idea - #OcugenMy trading idea for - #Ocugen - BUY Entry: 0.95 USD Target: 8.00 USD (+720% profit) Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Institutional Trading of Ocugen A number of large investors have recently added their stakes in OCGN. JPMorgan Chase & Co. increased its holdings in Ocugen by 20.9% during the first quarter. JPMorgan Chase & Co. now owns 4,015,742 shares of the company's stock worth $13,251,000 after buying an additional 693,786 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in Ocugen during the first quarter worth about $47,000. Cetera Investment Advisers purchased a new stake in Ocugen during the first quarter worth about $50,000. Vanguard Group Inc. increased its holdings in Ocugen by 2.8% during the first quarter. Vanguard Group Inc. now owns 10,906,557 shares of the company's stock worth $35,991,000 after buying an additional 301,063 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new position in Ocugen during the first quarter worth about $34,000. Hedge funds and other institutional investors own 21.50% of the company's stock. Ocugen Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
NASDAQ:OCGNLong
by Traderherz-Analytics
2
OCUGENThe wyckoff method is a very accurate method, There are many variations and purposes--soley to liquidate others or take shares from retail or weak hands, To sell of shares to FOMO traders or breakout traders. Liquidating Other institutions or create misleading Bullish signals and prices to entice investors etc, etc. the real skill is identifying the purpose of price movement, its likely targets of short term liquidity, and long term goals in correspondence to News.
NASDAQ:OCGNShort
by Integrity_Investments
5
OCGN Earnings Tomorrow! $15 Strike Price calls! WOWOcugen is a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines. They announced yesterday that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results tomorrow, May 6, before the market opens. As soon as i saw the news, there were also 764 calls with a $15 strike price expiring jan 20 in the options chain. they paid a 11.5k premium paid for the calls. Considering that the price is 2.25, such an impressive out of the money bunch of calls made me think it was an insider information about something that could be released tomorrow. On 2/28/2022 S. Ramakanth from HC Wainwright gave a Buy rating for OCGN and a price target of $8.00, while Robert LeBoyer from Noble Financialhas a $15.00 price target. I`m extremely bullish on OCGN earnings tomorrow. Looking forward to read your opinion about it.
NASDAQ:OCGNLong
by TopgOptions
5
Ocugen ocgn Strong candles Big target 10.28hi all bro... OCUGEN firts target. 5.05 second 5.87 . and 6.10 big target:10.28 *****important- ***** thin line above price is the first target. thin line below price is support.. stop point. Fibonacci correction between the highest price and lowest fiat in the chart area are thick lines.. thick lines are hard support and hard resistances.. main target in fallen assets is the green line . decline in peak assets main target green line ********** thnks goodluck.. always stoploss ..
NASDAQ:OCGN
by Takaro
1
Ocugen $OCGN - The Roulette TheoryHere is an example of the "Roulette Theory" that I have created by myself. The Roulette Theory is very simple, it is a theory that works on the probability of the candle colours. When a roulette table spins, you have 3 options, Red, Black and Green ( ZERO). The probability of have many REDs is much lower than having more equal amounts of RED and Black. When a Roulette table has many REDs, it is in your favour mathematically and statistically to bet that a different colour appears. The same principal is used here in the "Roulette Theory". The Roulette Theory was created by Missed A Million in 2013 and has a high probability of success. In order to be most effective, the last candle close must be a spinning top doji (Cross Shaped) in the same colour as all other candlesticks.
NASDAQ:OCGNLong
by missedamillion
2
Ocugen sees strong support at $7.80Ocugen has tested support twice at the $7.80-$8.00 range. There was a sharp sell-off after WHO approval was announced, but it's likely that approval added $1-$2 to the consolidating price. Two important catalysts are on the horizon: Potential Canadian approval and USA pediatric EUA. Ocugen will resume a strong uptrend if either of these comes through. Historically, Ocugen likes to dip to oversold territory before the strong pump. This is already happening now. Ocugen's small supply and heavy short interest make it a good candidate for a parabolic run. If you can handle the volatility, I wouldn't sleep on this stock.
NASDAQ:OCGNLong
by ToastChamp
OCGN back to basicsOCGN kind of treading water for now. I think what we need to see are some rock-solid results from COVAXIN, which this rolling submission could be helpful in identifying. The Phase 3 results were interesting. With more warnings coming out about the current SOC EAU vaccines, another option might not be "too late" at this point. But a lot will clearly come down to the results. For now, speculation is probably playing a bigger role as we don't know much more beyond what Ocugen announced this week. Regardless, looking at chart levels, a quick Fib retracement shows a few "pain points" on the chart, namely the 618 fib that has been a frequent resistance level over the last few months. "On July 2nd, Ocugen reported new evidence from Bharat Biotech. The company shared positive results of its Phase 3 study of COVAXIN™; a whole virion inactivated COVID-19 vaccine candidate. According to the company, it demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%. “With the Delta variant becoming a dominant strain of COVID-19 in the United States, we believe that the Phase 3 efficacy results reported by Bharat Biotech demonstrate that COVAXIN™ has the potential to become an important option to expand protection against this emerging variant. Combining these data with the only Delta-variant results from a controlled Phase 3 clinical trial, evidence continues to support a favorable benefit-risk profile for COVAXIN™.” - Dr. Bruce Forrest, Acting Chief Medical Officer and a member of the vaccine scientific advisory board of Ocugen. " Quote Source: 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
NASDAQ:OCGN
by PennyStocks101